SITE012-0110

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE012 (BRA) (Dr. Kowalski) · consented 2022-07-01

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 60); relationship: Y

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-14 (study day 360); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-17 (study day 363); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-02-14 (study day 575); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-10-02 (study day 806); relationship: not assessed

severe serious reported 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-11-13 (study day 848); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.